Annual report pursuant to Section 13 and 15(d)

BALANCE SHEETS

v3.3.1.900
BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Current assets:    
Cash $ 7,857 $ 15,470
Receivables 4,213 3,968
Prepaid expenses and other current assets 174 145
Total current assets 12,244 19,583
Property and equipment, net 1,043 1,268
Total Assets 13,287 20,851
Current liabilities:    
Accounts payable 4,158 4,408
Accrued clinical trials expenses 341 254
Other accrued liabilities 354 329
Deferred contract revenue 0 1,671
Total current liabilities 4,853 6,662
Warrant liability 1,444 5,578
Total Liabilities $ 6,297 $ 12,240
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized, none issued and outstanding at December 31, 2015 and 2014. $ 0 $ 0
Common stock, at amounts paid-in, $0.001 par value per share; 125,000,000 shares authorized, 20,059,820 and 19,999,552 shares issued and outstanding at December 31, 2015 and 2014, respectively. 297,828 289,196
Additional paid-in capital 23,261 22,235
Accumulated deficit (314,099) (302,820)
Total stockholders’ equity 6,990 8,611
Total Liabilities and Stockholders’ Equity $ 13,287 $ 20,851